VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson’s disease

Alieva, Anelya Kh.; Rudenok, Margarita M.; Filatova, Elena V.; Karabanov, Alexander; Доронина, О. Б.; Доронина, К. С.; Колачева, А. А.; Ugrumov, M. V.; Иллариошкин, С.Н.; Slominsky, Petr; Шадрина, М. И.

doi:10.1038/s41598-020-57938-3

Cited by 21 publications

(16 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the findings of the present study, TER ATPase has also been reported in EVs released from various cancer cells [ 47 ] and its downregulation greatly reduces exosome secretion, suggesting targeting of TER ATPase as a new anti-tumor therapy approach [ 48 ]. Moreover, TER ATPase can serve as a biomarker for the development of pathology at the early clinical and preclinical stages of Parkinson’s disease in humans [ 49 ]. However, the role and diagnostic values of the EV TPx-1 and TER ATPase of E .…”

Section: Discussionmentioning

confidence: 99%

Proteomic profiling of serum extracellular vesicles identifies diagnostic markers for echinococcosis

Guo

Wang²,

Zhang³

et al. 2022

PLoS Negl Trop Dis

View full text Add to dashboard Cite

Echinococcosis is a parasitic disease caused by the metacestodes of Echinococcus spp. The disease has a long latent period and is largely underdiagnosed, partially because of the lack of effective early diagnostic approaches. Using liquid chromatography-mass spectrometry, we profiled the serum-derived extracellular vesicles (EVs) of E. multilocularis-infected mice and identified three parasite-origin proteins, thioredoxin peroxidase 1 (TPx-1), transitional endoplasmic reticulum ATPase (TER ATPase), and 14-3-3, being continuously released by the parasites into the sera during the infection via EVs. Using ELISA, both TPx-1 and TER ATPase were shown to have a good performance in diagnosis of experimental murine echinococcosis as early as 10 days post infection and of human echinococcosis compared with that of control. Moreover, TER ATPase and TPx-1 were further demonstrated to be suitable for evaluation of the prognosis of patients with treatment. The present study discovers the potential of TER ATPase and TPx-1 as promising diagnostic candidates for echinococcosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Proteomic profiling of serum extracellular vesicles identifies diagnostic markers for echinococcosis

Guo

Wang²,

Zhang³

et al. 2022

PLoS Negl Trop Dis

View full text Add to dashboard Cite

show abstract

“…Based on the literature review, we discover that some of these genes have been reported to be associated with PD. PACRG, TH, LRRK2, TNR, and VCP are reported in [35][36][37][38][39][40][41] . In addition, KCNJ2, APBB1, and DCTN1 genes are associated with neurodegenerative diseases [42][43][44] .…”

Section: /23mentioning

confidence: 92%

“…We used seven metrics for measuring the performance of our proposed system, which are accuracy (ACC), area under the curve (AUC), area under precision-recall curve (AUPR), F1-Score, Matthews correlation coefficient (MCC), sensitivity (SEN), and specificity (SPC) 33,34 , which are defined by equations (33)• • • (40).…”

Section: Evaluation Metricsmentioning

confidence: 99%

Predicting Parkinson’s Disease Related Genes Based on PyFeat and Gradient Boosted Decision Tree (GBDT)

Helmy

El-Daydamony

Mekky

et al. 2022

Preprint

View full text Add to dashboard Cite

Identifying genes related to Parkinson's disease (PD) is an active and effective research topic in biomedical analysis, which plays a critical role in diagnosis and treatment. In recent years, many studies have proposed different techniques for predicting disease-related genes. However, a few of these techniques are designed or developed for PD gene prediction. Most of these PD techniques are developed to identify only protein genes and discard long non-coding (lncRNA) genes, which play an essential role in biological processes and the Transformation and development of diseases. This paper proposes a novel prediction system to identify protein and lncRNA genes related to PD that can aid in an early diagnosis. First, we preprocessed the genes into DNA FASTA sequences from the UCSC genome browser and removed the redundancies. Second, we extracted some significant features of DNA FASTA sequences using five numerical mapping techniques with Fourier transform and PyFeat method with Adaboost technique as feature selection. Finally, the features were fed to the gradient boosted decision tree (GBDT) to diagnose different tested cases. Seven performance metrics are used to evaluate the performance of the proposed system. The proposed system achieved an average accuracy (ACC) equals 78.1%, the area under the curve (AUC) equals 84.9%, the area under precision-recall (AUPR) equals 85.0%, F1-score equals 78.2%, Matthews correlation coefficient (MCC) equals 0.564, Sensitivity (SEN) equals 79.1%, and specificity (SPC) equals 77.1%. The experiments demonstrate promising results compared with other systems. The predicted top-rank protein and lncRNA genes are verified based on a literature review.

show abstract

“…To test this methodology, we used neurotoxic animal models of clinical and preclinical stages of PD, which are characterized by threshold and subthreshold degradation of the nigrostriatal dopaminergic system, respectively. [51][52][53][117][118][119][120][121] In this case, PD was reproduced in mice C57BL by systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), converted in the body to 1-methyl-4-phenylpyridinium, a toxin of dopaminergic neurons (Figure 1C,D). 116,122 Testing of this methodology showed that among 13 biomarkers found in untreated PD patients at the clinical stage, such as changes in plasma concentrations of catecholamines and amino acid neurotransmitters, as well as expression of specific genes in lymphocytes, 7 and 3 biomarkers were characteristics of models of PD at the clinical and preclinical stage, respectively.…”

Section: Searching For Biomarkers In Body Fluids In Patients and Animal Modelsmentioning

confidence: 99%

Development of early diagnosis of Parkinson's disease: Illusion or reality?

Ugrumov

2020

CNS Neurosci Ther

View full text Add to dashboard Cite

The fight against neurodegenerative diseases, Alzheimer disease and Parkinson's disease (PD), is a challenge of the 21st century. The low efficacy of treating patients is due to the late diagnosis and start of therapy, after the degeneration of most specific neurons and depletion of neuroplasticity. It is believed that the development of early diagnosis (ED) and preventive treatment will delay the onset of specific symptoms. This review evaluates methodologies for developing ED of PD. Since PD is a systemic disease, and the degeneration of certain neurons precedes that of nigrostriatal dopaminergic neurons that control motor function, the current methodology is based on searching biomarkers, such as premotor symptoms and changes in body fluids (BF) in patients. However, all attempts to develop ED were unsuccessful. Therefore, it is proposed to enhance the current methodology by (i) selecting among biomarkers found in BF in patients at the clinical stage those that are characteristics of animal models of the preclinical stage, (ii) searching biomarkers in BF in subjects at the prodromal stage, selected by detecting premotor symptoms and failure of the nigrostriatal dopaminergic system. Moreover, a new methodology was proposed for the development of ED of PD using a provocative test, which is successfully used in internal medicine.

show abstract

VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson’s disease

Cited by 21 publications

References 54 publications

Proteomic profiling of serum extracellular vesicles identifies diagnostic markers for echinococcosis

Proteomic profiling of serum extracellular vesicles identifies diagnostic markers for echinococcosis

Predicting Parkinson’s Disease Related Genes Based on PyFeat and Gradient Boosted Decision Tree (GBDT)

Development of early diagnosis of Parkinson's disease: Illusion or reality?

Contact Info

Product

Resources

About